IETDC
IETDC is a caspase 8-responsive fluorescent probe. IETDC is cleaved by activated caspase 8 to release D-cysteine, which then reacts with 6-hydroxy-2-cyanobenzothiazole (HCBT) to form firefly luciferin in situ. IETDC must be used in conjunction with PCL-2 (HY-D3168) to detect the co-existence of hydrogen peroxide and caspase 8. IETDC is applicable to studies related to acute inflammation.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1476735-95-1
- Formule: C32H47N5O13S
- Masse moléculaire:741.81
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
|
Caspase-8 |
IETDC (5 μM; 60 min) is selectively cleaved by recombinant caspase 8 but not caspase 3 or caspase 9 to release D-cysteine, which forms luciferin with HCBT to produce a ca. 27-fold increase in bioluminescent signal, and this response is fully inhibited by a pan-caspase inhibitor[1].
IETDC (10 μM; 60 min) acts as part of an AND-type molecular logic gate, producing an ca. 18-fold increase in bioluminescent signal only when combined with PCL-2, hydrogen peroxide, and active caspase 8, with signal blocked by inhibition of either hydrogen peroxide-mediated PCL-2 cleavage or caspase 8-mediated IETDC cleavage[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
IETDC (0.05 μmol; i.p.; single dose), co-administered with PCL-2, produces a 2.7-fold bioluminescent signal increase in female FVB-luc+ mice with LPS (HY-D1056)-induced acute inflammation, which is 30% attenuated by co-treatment with ascorbic acid and a pan-caspase inhibitor[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:FVB-luc+ (female, 2-5 months old)[1]
-
Dosage:0.05 μmol (co-administered with 0.05 μmol HCBT)
-
Administration:i.p.; single dose
-
Result:Produced an 18-fold increase in bioluminescent signal in lipopolysaccharide-treated mice compared to saline-treated controls.
Caused a 34% attenuation of the elevated bioluminescent signal when pre-treated with z-VD(OMe)-OPh.
-
Animal Model:FVB-luc+ (female, 2-5 months old)[1]
-
Dosage:0.05 μmol (co-administered with 0.05 μmol PCL-2)
-
Administration:i.p.; single dose
-
Result:Produced a 2.7-fold increase in bioluminescent signal in lipopolysaccharide-treated mice compared to saline-treated controls.
Caused a 30% attenuation of the elevated bioluminescent signal when co-treated with ascorbic acid and z-VD(OMe)-OPh.
Chemical Information
-
CAS No. 1476735-95-1
-
Masse moléculaire 741.81
-
Formule C32H47N5O13S
-
Sequence
Cbz-Ile-{Glu(Me)}-Thr-{Asp(Me)}-{d-Cys}
-
Sequence Shortening
Cbz-I-{Glu(Me)}-T-{Asp(Me)}-{d-Cys}
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
IETDC Related Classifications
HY-D3169 Related Classifications
Powered by Bioz